# **Screening Libraries**

# **Proteins**

**Product** Data Sheet

# NH-bis(PEG2-propargyl)

Cat. No.: HY-140088 CAS No.: 2100306-83-8 Molecular Formula:  $C_{14}H_{23}NO_{4}$ 

Molecular Weight: 269.34

**PROTAC Linkers** Target:

Pathway: **PROTAC** 

4°C, protect from light Storage:

\* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

# **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 50 mg/mL (185.64 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.7128 mL	18.5639 mL	37.1278 mL
	5 mM	0.7426 mL	3.7128 mL	7.4256 mL
	10 mM	0.3713 mL	1.8564 mL	3.7128 mL

Please refer to the solubility information to select the appropriate solvent.

# **BIOLOGICAL ACTIVITY**

Descri	ntion

 $NH-bis(PEG2-propargyl)\ is\ a\ PEG-based\ PROTAC\ linker\ that\ can\ be\ used\ in\ the\ synthesis\ of\ PROTACs^{[1]}.\ NH-bis(PEG2-propargyl)\ is\ a\ PEG-based\ PROTAC\ linker\ that\ can\ be\ used\ in\ the\ synthesis\ of\ PROTACs^{[1]}.$ propargyl) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

### IC<sub>50</sub> & Target

**PEGs** 

# In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com